Rajesh Pahwa (University of Kansas Medical Center) discusses the management of dyskinesia in Parkinson’s disease with a focus on amantadine (GOCOVRI™), the first and only FDA-approved medication for this indication.
1. What is the mechanism of action of amantadine in dyskinesia? (0:11)
2. What were the major findings of the two pivotal studies that led to the approval of GOCOVRI™ (amantadine) extended release capsules? (0:51)
3. Could you tell us a little about the pharmacokinetic profile of GOCOVRI™ and its recommended dosing regimen to achieve optimal dyskinesia control? (2:06)
4. How does the extended release formulation contribute to the tolerability of amantadine? (3:12)
5. What is the effect of GOCOVRI™ on non-motor symptoms in patients with Parkinson’s disease? (4:02)
Speaker disclosures: Rajesh Pahwa has received consulting fees from Abbvie, ACADIA, Acorda, Adamas, Cynapses, Global Kinetics, Lundbeck, Neurocrine, Pfizer, Sage, Sunovion, Teva Neuroscience, and US World Meds. Dr. Pahwa has received personal compensation in an editorial capacity as the Co-Editor-In-Chief of the International Journal of Neuroscience. Dr. Pahwa has received research support from Abbvie, Adamas, Avid, Biotie, Boston Scientific, Cala Health, Civitas, Cynapses, Kyowa, National Parkinson Foundation, NIH/NINDS, Parkinson Study Group, and Pfizer.
Filmed at the American Academy of Neurology (AAN) Annual Meeting 2018, Los Angeles, CA, US, April 2018.
Share this Video
Related Videos In Parkinson's Disease
Veronica Clark, Parkinson’s Europe: Presidential Update, and the Parkinson’s Manifesto for Europe
The European Parkinson’s Disease Association (EPDA) recently changed its name to Parkinson’s Europe. They are the only European Parkinson’s umbrella organisation and have been working with the global Parkinson’s community for nearly 30 years. As a leading voice for Parkinson’s in Europe, they provide trusted information; advance and share good practices; raise awareness and improve […]
Suman Kushwaha, MDS 2022: COVID-19 vaccine induced parkinsonism and cognitive dysfunction
Two cases of COVID-19 vaccination associated neurological symptoms were presented, with patients displaying parkinsonism and cognitive dysfunction. In this touchNEUROLOGY interview, we speak with Dr Suman Kushwaha (Institute of Human Behaviour and Allied Sciences (IHBAS), Dilshad Garden, Delhi, India) to discuss the neurological symptoms and investigations leading to the case report conclusions. The abstract entitled […]
Suman Kushwaha, MDS 2022: Neurological symptoms and COVID-19 vaccination
Neurological complications, such as peripheral neuropathy, have been associated with COVID-19 vaccination. In this touchNEUROLOGY interview, we speak with Dr Suman Kushwaha (Institute of Human Behavior and Allied Sciences (IHBAS), Dilshad Garden, Delhi, India) to discuss the neurological symptoms that have been observed. The abstract entitled ‘Covid vaccine induced parkinsonism and cognitive dysfunction’ was presented […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!